Table 1 Characteristics of the patients at randomization
Characteristic | Delayed strategy | Early strategy |
|---|---|---|
n = 550 | n = 557 | |
Study | ||
AKIKI | 308 (56.0) | 311 (55.8) |
IDEAL-ICU | 242 (44.0) | 246 (44.2) |
Age—year | 67.7 (13.2) | 66.5 (13.3) |
Weight—kg | 81.6 (22.2) | 82.4 (22.2) |
Male sex | 352 (64.0) | 351 (63.0) |
Pre-existing conditions | ||
Heart failure | 52 (9.5) | 44 (7.9) |
Hypertension | 304 (55.3) | 306 (54.9) |
Diabetes mellitus | 92 (16.7) | 112 (20.1) |
Cirrhosis | 54 (9.8) | 54 (9.7) |
Respiratory disease | 54 (9.8) | 62 (11.1) |
Cancer | 100 (18.2) | 91 (16.3) |
Hemopathy | 27 (4.9) | 34 (6.1) |
AIDS | 2 (0.4) | 5 (0.9) |
Non-corticosteroid immunosuppressive drug | 36 (6.5) | 32 (5.7) |
Organ graft | 17 (3.1) | 5 (0.9) |
Severity at enrollment | ||
SOFA score (0 to 24) | 11.5 (3.1) | 11.4 (3.2) |
Respiratory SOFA (0 to 4) | 2.1 (1.1) | 1.9 (1.1) |
Hemodynamic SOFA (0 to 4) | 3.5 (1.2) | 3.5 (1.2) |
Liver SOFA (0 to 4) | 0.8 (1.1) | 0.8 (1.1) |
Coagulation SOFA (0 to 4) | 2.1 (1.6) | 2.2 (1.6) |
Neurologic SOFA (0 to 4) | 1.3 (1.5) | 1.2 (1.5) |
Laboratory values | ||
Baseline creatinine (IQR), μmol/L* | 88 (71–97) | 84 (71–97) |
Creatinine at enrollment (IQR), μmol/L | 268 (211–343) | 267 (198–352) |
Blood urea nitrogen at enrollment (IQR), mmol/L | 19 (14–26) | 19 (13–26) |
Potassium at enrollment, mmol/L | 4.4 (0.8) | 4.4 (0.8) |
Bicarbonate at enrollment, mmol/L | 18 (5) | 18 (5) |
Arterial blood pH at enrollment | 7.30 (0.10) | 7.30 (0.10) |